Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 3 clinical trials
Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease

, importantly, enable reduction and potentially clearance of Fabry disease substrates Gb3 and lyso-Gb3. On Day 1, patients will be infused intravenously with a single dose of ST-920 and followed for a period of

acroparesthesia
alpha-galactosidase
anhidrosis
cornea verticillata
angiokeratoma
  • 114 views
  • 29 Apr, 2022
  • 12 locations
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy

In Fabry disease (FD), -galactosidase A deficiency leads to the accumulation of globotriaosylceramide (Lyso-Gb3 and Gb3), triggering a pathologic cascade that causes progressive damage to

  • 0 views
  • 05 Feb, 2021
  • 1 location
Early Detection and Follow-Up of Patients With Fabry's Disease

deepen our knowledge of the correlation among Lyso-Gb3, genotype and phenotype. Better understanding of the pathophysiology of FD. To sum up, the results of the study will make a significant

  • 0 views
  • 28 Apr, 2021
  • 1 location